Organogenesis Holdings Inc. 8-K Summary
Business Context and Reporting Period
Organogenesis Holdings Inc. (ORGO) filed this Form 8-K on February 26, 2026, to announce its financial results for the fiscal fourth quarter and the full fiscal year ended December 31, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
Specific material changes versus the prior comparable period are not detailed in this filing. The document serves solely as a notification that the results have been announced via a separate press release.
Guidance, Outlook, and Risks
This filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. Such information, if provided, is located in the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 26, 2026) for actual financial figures.
- Verify the specific revenue and net income figures for Q4 and full-year 2025.
- Check for any updated financial guidance or operational outlook provided in the press release.
- Confirm the status of cash flow and liquidity positions as reported in the full earnings release.